How much funding has Ethris raised?

Ethris has raised $69.3M in total funding, most recently a Corporate Round.

Who are Ethris's investors?

Ethris's investors include Cipla, Laureus Capital, OrbiMed.

Where is Ethris headquartered?

Ethris is headquartered in Munich, Germany.

Ethris

Paving a new path from genes to therapeutic proteins

Munich, Germany · Founded 2009 · $69.3M raised

Biotech

Headquarters: Munich
Employees: 11–50
Founded: 2009
Business Model: B2B

Website: ethris.com
Total Funding: $69.3M
Last Round: $15.0M Corporate RoundJan 2025
Rounds: 4

About

Ethris GmbH is a clinical-stage biotechnology company based in Planegg near Munich, Germany, pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines for severe respiratory diseases. Founded by Dr. Carsten Rudolph and Prof. Dr. Christian Plank, Ethris developed its proprietary SNIM® RNA and SNaP LNP® delivery platforms, which enable multi-route administration of mRNA including differentiated inhaled delivery directly to the lungs—a key differentiator for treating conditions such as asthma and COPD. The company has entered strategic collaborations with major partners including AstraZeneca and MedImmune to advance its mRNA programs, and its lead asset ETH47 targets the prevention of asthma exacerbations.

Summary

Ethris is a Biotech company based in Munich, Germany, founded in 2009. It has raised $69.3M in total across 4 rounds, most recently a $15.0M Corporate Round round in Jan 2025. Investors include Cipla, Laureus Capital and OrbiMed.